Device makers take big writedowns on renal denervation

Boston Scientific, Medtronic and Covidien take millions in write-downs on their renal denervation assets after the failure of Medtronic's Symplicity-3 trial.

Boston Scientific, Covidien, Medtronic, St. Jude Medical

News Well, Hypertension, Wall Street Beat

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1sJAWe5